Gary Reedy has a big turnaround project on his hands.
As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.
The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.
As a cancer patient advocacy organization—especially one dedicated to a category of malignancies that have seen frustratingly slow progress and only negligible improvements in survival rates over the past four-plus decades—we've come to view our role and responsibility to the brain tumor community as something like that of a plumber.
Marsha Fountain, retired president of The Oncology Group, died Jan. 7 after a long struggle with metastatic breast cancer. She was 65.
Robert W. Day, former president and director of Fred Hutch.Photo courtesy of Fred Hutchinson Cancer Research CenterRobert W. Day, the longestserving president and director of Fred Hutchinson Cancer Research Center, died at his home Jan. 6 of non-small cell squamous carcinoma. He was 87.
The Roche-Syapse collaboration to develop analytics programs may enable health systems to measure the impact of precision therapies, said Damon Hostin, CEO of the Precision Medicine Alliance.
Syapse and Roche are working on building software that would allow health systems to incorporate real-world evidence into Syapse's platform in an effort to develop true clinical decision support for precision therapies.
Roche has teamed up with the precision medicine company Syapse to develop software for measuring health outcomes and economic impact of precision medicine.
Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.
